Harvard Medical School, Associate Professor
BIND Biosciences and Selecta Biosciences, Co-Founder
Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and directs the Laboratory of Nanomedicine and Biomaterials at Brigham and Women’s Hospital (BWH). Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored more than 60 papers and is an inventor of more than 40 issued/pending patents. The technologies that Dr. Farokhzad has developed the foundation for the launch of two venture-backed biotechnology companies, BIND Biosciences and Selecta Biosciences. These companies are translating the aforementioned academic innovations towards clinical development. He serves as Director on the board of BIND and as Director and Vice Chairman on the board of Selecta. Dr. Farokhzad was named among the Nano50 winners of 2007 by Nanotech Briefs and in 2009 he was among the 15 recipients across all industries to receive the All Star Distinguished Achievement Award, from the Mass High Tech (MHT) Journal for his contributions to Life Sciences industry. Dr. Farokhzad completed his post-doctoral clinical and research trainings, respectively, at BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.